{"title":"妊娠期血浆维生素a与妊娠期糖尿病的关系。","authors":"Xiang Cheng, Hongyan Cui, Xinran Xu, Nini Jiang","doi":"10.5603/gpl.103660","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>We investigated the correlation of plasma Afamin levels with gestational diabetes mellitus (GDM) during pregnancy and assessed its predictive value for the risk and prognosis of GDM.</p><p><strong>Material and methods: </strong>A total of 993 pregnant women were included in this nested case-control study. The fasting blood samples in their first trimester were collected. Ninety-one women were diagnosed with GDM, and they were subdivided into insulin treatment group (Group A1, 30 cases) and non-insulin treatment group (Group A2, 61 cases) according to whether they needed to treat with insulin. Another 91 pregnant women with normal glucose tolerance were as the control group (NC group). The plasma and umbilical cord blood levels of Afamin were measured in the first and second trimesters using enzyme-linked immunosorbent assay (ELISA). The correlation of Afamin levels with GDM during pregnancy and its predictive value were assessed.</p><p><strong>Results: </strong>Plasma Afamin levels in both GDM groups (A1 and A2) were significantly higher than in the control group at all pregnancy stages (p < 0.01). Afamin levels in the second trimester were significantly higher in Group A1 than those in Group A2 (p < 0.05). Multivariate logistic regression identified that plasma Afamin levels in the first trimester (OR = 1.126, 95% CI: 1.032-1.228, p = 0.008) and in the second trimester (OR = 1.173, 95% CI: 1.092-1.259, P = 0.000) were the independent risk factors for GDM, along with insulin resistance index (OR = 1.62, 95% CI: 1.036-2.534, p = 0.034). ROC analysis showed optimal cut-off value of plasma Afamin was 65.90 mg/L in the first trimester (AUC = 0.858, sensitivity = 75.8%, specificity = 85.7%) and 85.09 mg/L in the second trimester (AUC = 0.874, sensitivity = 92.3%, specificity = 76.9%).</p><p><strong>Conclusions: </strong>Elevated plasma Afamin levels during the first and second trimesters are associated with GDM, supporting Afamin level as a potential biomarker for early GDM risk prediction.</p>","PeriodicalId":94021,"journal":{"name":"Ginekologia polska","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correlation between plasma Afamin and gestational diabetes mellitus during pregnancy.\",\"authors\":\"Xiang Cheng, Hongyan Cui, Xinran Xu, Nini Jiang\",\"doi\":\"10.5603/gpl.103660\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>We investigated the correlation of plasma Afamin levels with gestational diabetes mellitus (GDM) during pregnancy and assessed its predictive value for the risk and prognosis of GDM.</p><p><strong>Material and methods: </strong>A total of 993 pregnant women were included in this nested case-control study. The fasting blood samples in their first trimester were collected. Ninety-one women were diagnosed with GDM, and they were subdivided into insulin treatment group (Group A1, 30 cases) and non-insulin treatment group (Group A2, 61 cases) according to whether they needed to treat with insulin. Another 91 pregnant women with normal glucose tolerance were as the control group (NC group). The plasma and umbilical cord blood levels of Afamin were measured in the first and second trimesters using enzyme-linked immunosorbent assay (ELISA). The correlation of Afamin levels with GDM during pregnancy and its predictive value were assessed.</p><p><strong>Results: </strong>Plasma Afamin levels in both GDM groups (A1 and A2) were significantly higher than in the control group at all pregnancy stages (p < 0.01). Afamin levels in the second trimester were significantly higher in Group A1 than those in Group A2 (p < 0.05). Multivariate logistic regression identified that plasma Afamin levels in the first trimester (OR = 1.126, 95% CI: 1.032-1.228, p = 0.008) and in the second trimester (OR = 1.173, 95% CI: 1.092-1.259, P = 0.000) were the independent risk factors for GDM, along with insulin resistance index (OR = 1.62, 95% CI: 1.036-2.534, p = 0.034). ROC analysis showed optimal cut-off value of plasma Afamin was 65.90 mg/L in the first trimester (AUC = 0.858, sensitivity = 75.8%, specificity = 85.7%) and 85.09 mg/L in the second trimester (AUC = 0.874, sensitivity = 92.3%, specificity = 76.9%).</p><p><strong>Conclusions: </strong>Elevated plasma Afamin levels during the first and second trimesters are associated with GDM, supporting Afamin level as a potential biomarker for early GDM risk prediction.</p>\",\"PeriodicalId\":94021,\"journal\":{\"name\":\"Ginekologia polska\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ginekologia polska\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5603/gpl.103660\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ginekologia polska","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/gpl.103660","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Correlation between plasma Afamin and gestational diabetes mellitus during pregnancy.
Objectives: We investigated the correlation of plasma Afamin levels with gestational diabetes mellitus (GDM) during pregnancy and assessed its predictive value for the risk and prognosis of GDM.
Material and methods: A total of 993 pregnant women were included in this nested case-control study. The fasting blood samples in their first trimester were collected. Ninety-one women were diagnosed with GDM, and they were subdivided into insulin treatment group (Group A1, 30 cases) and non-insulin treatment group (Group A2, 61 cases) according to whether they needed to treat with insulin. Another 91 pregnant women with normal glucose tolerance were as the control group (NC group). The plasma and umbilical cord blood levels of Afamin were measured in the first and second trimesters using enzyme-linked immunosorbent assay (ELISA). The correlation of Afamin levels with GDM during pregnancy and its predictive value were assessed.
Results: Plasma Afamin levels in both GDM groups (A1 and A2) were significantly higher than in the control group at all pregnancy stages (p < 0.01). Afamin levels in the second trimester were significantly higher in Group A1 than those in Group A2 (p < 0.05). Multivariate logistic regression identified that plasma Afamin levels in the first trimester (OR = 1.126, 95% CI: 1.032-1.228, p = 0.008) and in the second trimester (OR = 1.173, 95% CI: 1.092-1.259, P = 0.000) were the independent risk factors for GDM, along with insulin resistance index (OR = 1.62, 95% CI: 1.036-2.534, p = 0.034). ROC analysis showed optimal cut-off value of plasma Afamin was 65.90 mg/L in the first trimester (AUC = 0.858, sensitivity = 75.8%, specificity = 85.7%) and 85.09 mg/L in the second trimester (AUC = 0.874, sensitivity = 92.3%, specificity = 76.9%).
Conclusions: Elevated plasma Afamin levels during the first and second trimesters are associated with GDM, supporting Afamin level as a potential biomarker for early GDM risk prediction.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
